Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats
Identifieur interne : 003304 ( Main/Curation ); précédent : 003303; suivant : 003305Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats
Auteurs : A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada]Source :
- Experimental neurology : (Print) [ 0014-4886 ] ; 2001.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
The most widely used immunosuppressant in neural transplantation is cyclosporine- A (CsA). However, CsA has significant toxic effects when administered systemically. Tacrolimus (FK506), is a more potent immunosuppressant than CsA and can be prepared in lipid micelles (LTAC). This liposomal preparation allows for the administration of tacrolimus to the site of transplantation, possibly reducing the systemic side effects of immunosuppression. In this study we investigated the ability of LTAC to promote graft survival in hemiparkinsonian rats implanted with fetal mouse xenografts when LTAC is administered systemically to the host, when added to the donor cell suspension, or in combination. Rats with unilateral 6-hydroxydopamine lesions were transplanted with 800,000 fetal mouse ventral mesencephalic (VM) cells and were randomly divided into four groups. Group 1 was not immunosuppressed; Group 2 received daily systemic injections of LTAC; Group 3 received LTAC within the cell suspensions of mouse VM cells; and Group 4 received LTAC in the cell suspensions along with daily systemic administration of LTAC. Transplanted rats were assessed for rotational behavior 3 and 6 weeks posttransplantation. Cell survival was assessed using tyrosine hydroxylase (TH) immunohistochemistry. A significant reduction in rotational scores was observed only in the group of animals receiving the combination of LTAC-treated donor cells and systemic LTAC administration. This functional improvement correlated with a significantly greater survival of TH-immunoreactive cells in this group of animals. The other groups had poor cell survival and no significant functional improvement. We conclude that a combination of systemic immunosuppression and treatment of the cell suspension with LTAC may be a superior strategy to optimize xenograft survival. This strategy may have important implications for clinical neural transplantation.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B86
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000137
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A83
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003790
Links to Exploration step
Pascal:02-0290345Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats</title><author><name sortKey="Alemdar, A Y" sort="Alemdar, A Y" uniqKey="Alemdar A" first="A. Y." last="Alemdar">A. Y. Alemdar</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Baker, K A" sort="Baker, K A" uniqKey="Baker K" first="K. A." last="Baker">K. A. Baker</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Sadi, D" sort="Sadi, D" uniqKey="Sadi D" first="D." last="Sadi">D. Sadi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Mcalister, V C" sort="Mcalister, V C" uniqKey="Mcalister V" first="V. C." last="Mcalister">V. C. Mcalister</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of General Surgery, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Mendez, I" sort="Mendez, I" uniqKey="Mendez I" first="I." last="Mendez">I. Mendez</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurosurgery, Department of Surgery, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">02-0290345</idno><date when="2001">2001</date><idno type="stanalyst">PASCAL 02-0290345 INIST</idno><idno type="RBID">Pascal:02-0290345</idno><idno type="wicri:Area/PascalFrancis/Corpus">000B86</idno><idno type="wicri:Area/PascalFrancis/Curation">000137</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000A83</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000A83</idno><idno type="wicri:doubleKey">0014-4886:2001:Alemdar A:liposomal:tacrolimus:administered</idno><idno type="wicri:Area/Main/Merge">003790</idno><idno type="wicri:Area/Main/Curation">003304</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats</title><author><name sortKey="Alemdar, A Y" sort="Alemdar, A Y" uniqKey="Alemdar A" first="A. Y." last="Alemdar">A. Y. Alemdar</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Baker, K A" sort="Baker, K A" uniqKey="Baker K" first="K. A." last="Baker">K. A. Baker</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Sadi, D" sort="Sadi, D" uniqKey="Sadi D" first="D." last="Sadi">D. Sadi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Mcalister, V C" sort="Mcalister, V C" uniqKey="Mcalister V" first="V. C." last="Mcalister">V. C. Mcalister</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Division of General Surgery, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>4 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author><author><name sortKey="Mendez, I" sort="Mendez, I" uniqKey="Mendez I" first="I." last="Mendez">I. Mendez</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neural Transplantation Laboratory, Department of Anatomy and Neurobiology, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Division of Neurosurgery, Department of Surgery, Dalhousie University</s1><s2>Halifax, Nova Scotia, B3H 4H7</s2><s3>CAN</s3><sZ>5 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Halifax, Nova Scotia, B3H 4H7</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Experimental neurology : (Print)</title><title level="j" type="abbreviated">Exp. neurol. : (Print)</title><idno type="ISSN">0014-4886</idno><imprint><date when="2001">2001</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title><title level="j" type="abbreviated">Exp. neurol. : (Print)</title><idno type="ISSN">0014-4886</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aminoacid</term><term>Animal</term><term>Chemotherapy</term><term>Ciclosporin</term><term>Heterograft</term><term>Immunohistochemistry</term><term>Immunosuppression</term><term>Immunosuppressive agent</term><term>Implant</term><term>Lactone</term><term>Macrocycle</term><term>Mouse</term><term>Parkinson disease</term><term>Rat</term><term>Survival</term><term>Tacrolimus</term><term>Toxicity</term><term>Treatment</term><term>Tyrosine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Tacrolimus</term><term>Hétérogreffe</term><term>Ciclosporine</term><term>Tyrosine</term><term>Immunohistochimie</term><term>Parkinson maladie</term><term>Chimiothérapie</term><term>Implant</term><term>Immunodépresseur</term><term>Survie</term><term>Rat</term><term>Animal</term><term>Toxicité</term><term>Immunodépression</term><term>Souris</term><term>Lactone</term><term>Macrocycle</term><term>Aminoacide</term><term>Traitement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The most widely used immunosuppressant in neural transplantation is cyclosporine- A (CsA). However, CsA has significant toxic effects when administered systemically. Tacrolimus (FK506), is a more potent immunosuppressant than CsA and can be prepared in lipid micelles (LTAC). This liposomal preparation allows for the administration of tacrolimus to the site of transplantation, possibly reducing the systemic side effects of immunosuppression. In this study we investigated the ability of LTAC to promote graft survival in hemiparkinsonian rats implanted with fetal mouse xenografts when LTAC is administered systemically to the host, when added to the donor cell suspension, or in combination. Rats with unilateral 6-hydroxydopamine lesions were transplanted with 800,000 fetal mouse ventral mesencephalic (VM) cells and were randomly divided into four groups. Group 1 was not immunosuppressed; Group 2 received daily systemic injections of LTAC; Group 3 received LTAC within the cell suspensions of mouse VM cells; and Group 4 received LTAC in the cell suspensions along with daily systemic administration of LTAC. Transplanted rats were assessed for rotational behavior 3 and 6 weeks posttransplantation. Cell survival was assessed using tyrosine hydroxylase (TH) immunohistochemistry. A significant reduction in rotational scores was observed only in the group of animals receiving the combination of LTAC-treated donor cells and systemic LTAC administration. This functional improvement correlated with a significantly greater survival of TH-immunoreactive cells in this group of animals. The other groups had poor cell survival and no significant functional improvement. We conclude that a combination of systemic immunosuppression and treatment of the cell suspension with LTAC may be a superior strategy to optimize xenograft survival. This strategy may have important implications for clinical neural transplantation.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003304 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003304 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Curation
|type= RBID
|clé= Pascal:02-0290345
|texte= Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats
}}
| This area was generated with Dilib version V0.6.29. |  |